<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584920</url>
  </required_header>
  <id_info>
    <org_study_id>HLX01-NHL02</org_study_id>
    <nct_id>NCT02584920</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised, double-blind, parallel group study to compare PK and PD profiles between HLX01
      and rituximab (MabThera®) in patients with CD20+ B-cell Lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) for HLX01 and rituximab concentrations</measure>
    <time_frame>91 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Maximum Concentration (Cmax) of the HLX01 and rituximab</measure>
    <time_frame>91 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Anti-Drug Antibodies against HLX01</measure>
    <time_frame>91 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of CD19+ B-cells</measure>
    <time_frame>91 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>B-cell Non Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>HLX01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>375mg/m2 iv single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>375mg/m2 iv single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX01</intervention_name>
    <arm_group_label>HLX01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged from 18 to 65 years;

          2. CD20-positive non-Hodgkin's lymphoma (NHL);

          3. having obtained CR (complete remission) or CRu (uncertain complete remisson) after the
             prior therapy;

          4. ECOG performance status of &lt;=1, expected survival of at least &gt;= 3 months;

          5. Peripheral blood lymphocyte count &lt; 5×10^9/L

          6. signed an informed consent form which was approved by the institutional review board
             of the respective medical center .

        Exclusion Criteria:

          1. Other invasive malignancies within 5 years except for adequately treated basal cell or
             squamous cell skin cancer, in situ carcinoma of the cervix;

          2. Chemotherapy within 1 month;

          3. Had received rituximab or other anti-CD20(+) monoclonal antibody treatment within 1
             month before enrollment;

          4. Had received rituximab or other anti-CD20(+) monoclonal antibody treatment 1 month ago
             but with ADA(+) before enrollment;

          5. Blood concentration of Rituximab&gt; 24 μg/ml prior to study entry;

          6. Had received hematopoitic growth factor within 1 week prior to study entry;

          7. Receipt of a live/attenuated vaccine within 4 weeks prior to the Screening Visit;

          8. Recent major surgery (within 8 weeks prior to screening, excluding lymph node biopsy);

          9. Peripheral or central nervous system disease;

         10. Serious hematologic dysfunction (white blood cell count of &lt;3.0×109/L; absolute
             neutrophil count of &lt;1.5×109/L; platelet count of &lt; 100×109/L; hemoglobin level of &lt;
             9.0 g/dL);

         11. Hepatic dysfunction (total bilirubin level of &gt; 1.5 × upper limit of normal (ULN);
             aspartate amino transferase (AST) and alanine amino transferase (ALT) levels of &gt; 2.0
             × ULN; alkaline phosphatase &gt; 3.0 × ULN; renal dysfunction (serum creatinine level of
             &gt; 1.5×ULN );

         12. Abnormal thyroid function;

         13. Seropositive for HIV , HCV antibody; seropositive for hepatitis B virus surface
             antigen (HBsAg). HBV DNA&gt;1.0×103copies/ml;

         14. Serious underlying medical conditions, could impair the ability of the patient to
             participate in the trial (including but not limited to ongoing active infection,
             uncontrolled diabetes mellitus, significant cardiac disease, uncontrolled angina,
             gastric ulcers, active autoimmune disease);

         15. Pregnancy or breast feeding. For women of childbearing potential.

         16. History of a severe allergic reaction or anaphylactic reaction to a biological agent
             or history of hypersensitivity to any component of the trial drug.

         17. Subjects had a history of alcoholism or drug abuse;

         18. Researchers think that do not fit into the group.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2015</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

